Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

Journal of Urology

Volumn 172, Issue 3, 2004, Pages 888-893

  O'Donnell, Michael A ^a   Lilli, Kathleen ^b   Leopold, Christina ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

Bladder neoplasms; Drug therapy; Drug toxicity; Treatment outcome

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INDUCTION THERAPY; INFECTION; INFLAMMATION; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MUSCLE DISEASE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; SUPERFICIAL BLADDER CANCER; SUPERFICIAL CANCER;

EID: 4143151777     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000136446.37840.0a     Document Type: Article

References (16)

1. O'Donnell, M. A.: New therapeutic strategies for non-muscle-invasive (superficial) bladder cancer. AUA Update Series, XXII, lesson 2, 2003
2. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy in recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol, 163: 1124, 2000
3. Silvester, R. J., van der Meijden, A. P. M. and Lamm, D. L.: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 168: 1964, 2002
4. Böhle, A., Jocham, D. and Bock, P. R.: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol, 169: 90, 2003
5. Saint, F., Patard, J. J., Maille, P., Soyeux, P., Hoznek, A., Salomon, L. et al: Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol, 167: 364, 2002
6. Nadler, R., Luo, Y., Zhao, W., Ritchey, J. K., Austin, J. C., Cohen, M. B. et al: Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol, 131: 206, 2003
7. Brown, D. H., Wagner, T. T. and Bahnson, R. R.: Interferons and bladder cancer. Urol Clin North Am, 27: 171, 2000
8. Luo, Y., Chen, X., Downs, T. M., DeWolf, W. C. and O'Donnell, M. A.: IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol, 162: 2399, 1999
9. Bassi, P.: Methodology in superficial bladder cancer clinical trials. Objective evaluation of treatment: the need of standardization. In: Superficial Bladder Cancer. Edited by F. Pagano and W. R. Fair. Oxford: Isis Medical Media, chapt. 8, p. 82, 1997
10. O'Donnell, M. A., Krohn, J. and DeWolf, W. C.: Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol, 166: 1300, 2001
11. Luciani, L. G., Neulander, E., Murphy, W. M. and Wajsman, Z.: Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology, 58: 376, 2001
12. Lam, J. S., Benson, M. C., O'Donnell, M. A., Sawczuk, A., Gavazzi, A., Wechsler, M. H. et al: Bacillus Calmette-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol, 21: 354, 2003
13. Punnen, S. P., Chin, J. L. and Jewett, M. A.: Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol, 10: 1790, 2003
14. Steinberg, G., Bahnson, R., Brosman, S., Middleton, R., Wajsman, Z. and Wehle, M.: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol, 163: 761, 2000
15. Lamm, D. L., Steg, A., Boccon-Gibod, L., Morales, A., Hanna, M. G., Jr., Pagano, F. et al: Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res, 310: 335, 1989
16. Martinez-Pineiro, J. A., Flores, N., Isorna, S., Solsona, E., Sebastian, J. L., Pertusa, C. et al: Long-term follow-up of prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int, 89: 671, 2002